Hypofractionated Whole Breast Irradiation Underused

Share

According to a study published in JAMA, most breast cancer patients do not receive radiation
treatment that is shorter in duration and less costly, despite guidelines endorsing their use. The study was released at the San Antonio Breast
Cancer Symposium (TX, USA).

Breast cancer accounts for the largest portion of
national expenditures on cancer care. It is estimated that health care costs
associated with breast cancer will reach approximately $158 billion in
2020.

The most common treatment for early-stage breast
cancer is breast conservation therapy. Whole breast irradiation (WBI) is
recommended for most women who have gone through breast conserving surgery, as
it reduces local recurrence and improves the patient's overall survival rate.

Conventional WBI comprises five to seven weeks of daily
radiation fractions, while hypofractionated WBI is a shorter duration treatment
alternative that comprises fewer but higher-dose fractions. Hypofractionated
WBI is delivered over three weeks, and clinical evidence to date indicates its
effectiveness. Expert guidelines from 2011 also endorse the use of
hypofractionated WBI for selected patients with early-stage breast cancer.

The study was conducted by Justin E. Bekelman, MD, and colleagues at the University of Pennsylvania Perelman School of Medicine in Philadelphia. The study team examined the usage and costs of hypofractionated
WBI between 2008 and 2013 by reviewing the administrative claims data from 14
commercial healthcare plans covering 7.4 percent of adult women in the US in 2013.

They classified patients with incident early-stage
breast cancer treated with lumpectomy and WBI from 2008 and 2013 into two groups. The hypofractionation-endorsed cohort (n = 8,924) included patients 50
years of age or older without prior chemotherapy or axillary lymph node
involvement. The hypofractionation-permitted cohort (n = 6,719) included
patients younger than 50 years or those with prior chemotherapy or axillary
lymph node involvement. This analysis was based on a comparison of
hypofractionated WBI for three to five weeks and conventional WBI for five to seven weeks.

The study findings show that there was an increase in
hypofractionated WBI from 10.6 percent in 2008 to 34.5 percent in 2013 in the
hypofractionation-endorsed group, and from 8.1 percent in 2008 to 21.2 percent
in 2013 in the hypofractionation-permitted group. Total healthcare
expenditures in the first year after diagnosis were $28,747 for
hypofractionated and $31,641 for conventional WBI in the hypofractionation-endorsed
group, and $64,273 for hypofractionated and $72,860 for conventional WBI in the
hypofractionation-permitted group. As per the results of this study, the adjusted
average total one-year patient out-of-pocket expenses were not significantly
different between the two groups.

The study authors believe that while hypofractionated
and conventional WBI have been found to be equally effective for in-breast
tumor control and are also comparable in terms of long-term side effects,
hypofractionated WBI is not used very often because the 2011 practice
guidelines stop short of recommending its use in place of conventional WBI.
That is probably why the treatment alternative has had a slower uptake in the
US as compared to other countries.

Results from the largest international comparison of the treatment of elderly patients with breast cancer show that significant...
Read more

breast cancer, radiation therapy, breast conservation therapy, cancer care, hypofractionated whole breast irradiation
According to a study published in JAMA, most breast cancer patients do not receive radiation
treatment that is shorter in duration and less costly, despit

No comment

Highlighted Products

The HAMILTON-T1 combines for the first time the functionality of a fully featured intensive care unit ventilator with the compactness and ruggedness required for transport. This is why the HAMILTON-T1 enables you to provide optimal ventilation therapy...

The HAMILTON-C3 ventilator is a modular high-end ventilation solution for all patient groups. Offering a number of unique features, the HAMILTON-C3 is one of the first ventilators featuring the “Ventilation Autopilot” INTELLiVENT-ASV®. The HAMILTON-C3’s...

The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...